Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs
- 1 January 1993
- journal article
- Published by Taylor & Francis in Xenobiotica
- Vol. 23 (6) , 575-588
- https://doi.org/10.3109/00498259309059396
Abstract
1. Pharmacodynamic models relating the plasma concentrations (C) of radioactive heparin material to anticoagulant effect (E) have been investigated after single i.v. and s.c. doses of 3H-tinzaparin (1 and 4 mg/kg), a radiolabelled low molecular weight heparin, to six dogs. 2. A counterclockwise hysteresis, characterizing the C versus E relationship, was observed in all animals after s.c., but not i.v., doses indicating a possible delay (lag-time) in the systemic availability of pharmacologically-active heparin material following extravascular administration. A constant (Ke) was introduced into the model to account for this hysteresis. 3. At high plasma concentrations of radioactivity (> 10 micrograms/ml), E was related to C by a sum of two sigmoid Emax models, whereas, at lower concentrations, this reduced to the well-known sigmoid Emax model. It was proposed that tinzaparin activates two 'receptors' having different affinities for the drug. The values of EC50 associated with the activation of a single 'receptor' and of a proposed additional 'receptor' were 3 and 13 micrograms/ml of heparin material, respectively. 4. Heparin material was predominantly eliminated by renal excretion and underwent widespread tissue distribution. After s.c. administration, input of heparin material into systemic plasma was complete within 12 h post-dose, and the absorption process was characterized by a bi-exponential function. 5. We conclude that sigmoid Emax models adequately describe the C versus E relationship after s.c. and i.v. doses of 3H-tinzaparin in dogs and that the interindividual variation of the pharmacodynamic parameters derived from this model was relatively small.Keywords
This publication has 30 references indexed in Scilit:
- Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin® (LMWH) or unfractionated heparinThrombosis Research, 1992
- Noncompartmental Versus Compartmental Modelling in Clinical PharmacokineticsClinical Pharmacokinetics, 1991
- The disappearance of a low molecular weight heparin fraction (cy 216) differs from standard heparin in rabbitsThrombosis Research, 1987
- Heparin half‐life and sensitivity in normal subjects and in patients affected by deep vein thrombosisEuropean Journal of Clinical Investigation, 1986
- Bioavailability and antagonization of the low molecular weight heparin CY 216 in manThrombosis Research, 1986
- Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administrationThrombosis Research, 1985
- Anticoagulant and lipolytic effects of a low molecular weight heparin fractionThrombosis Research, 1985
- Evaluation of a computer-assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic modelClinical Pharmacology & Therapeutics, 1982
- Linear systems analysis in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1978
- The heterogeneity of the anticoagulant response to heparinJournal of Clinical Pathology, 1972